Antibodies binding to ILT4

US11401328B2 · kind B2 · utility

Assignees

• Five Prime Therapeutics, Inc. · US
• Bristol-Myers Squibb Company · US

Inventors

• Xiao Min Schebye · Palomar Park, US
• Diana Yuhui Chen · San Francisco, US
• Andrew Rankin · Redwood City, US
• Xiaodi Deng · San Mateo, US
• Joseph Toth · Belmont, US
• Linda Liang · Mountain View, US
• Michelle Minhua HAN · Piedmont, US
• Christine Bee · San Francisco, US
• Hong-An TRUONG · San Francisco, US
• Mark J. Selby · San Francisco, US
• Nils Lonberg · Woodside, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Ekaterina Deyanova · Lawrenceville, US
• Alan J. Korman · Piedmont, US

Key dates

• Filing date: Jul 9, 2019
• Grant date: Aug 2, 2022
• Expiry date: Feb 12, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.